Targeting of saporin to CD25-positive normal and neoplastic lymphocytes by an anti-saporin/anti-CD25 bispecific monoclonal antibody: in vitro evaluation P.L. Tazzaril3, S. Zhang"2, Q. Chenl2, S. Sforzinil, A. Summary This study has been designed to verify the specific toxicity of saporin, a type I ribosomeinactivating protein (RIP), with the same activity as ricin A chain, targeted by a bispecific monoclonal antibody (bimAb) recognising both the CD25 antigen and the RIP.
The CD25 antigen is expressed by lymphoid populations upon activation and by leukaemias and lymphomas with an activated membrane phenotype (Hodgkin's lymphoma, anaplastic large cell lymphoma, adult T cell leukaemia). The bimAb-saporin mixture was tested on CD25 + targets at different bimAb and saporin concentrations. Saporin, in the presence of a bimAb concentration of lo-9 M, inhibited protein synthesis by CD25 + neoplastic lymphocytes (L540 and MT2 cell lines) with ICms (concentrations giving 50% of inhibition) ranging from 8 x 10 -2 M to 3 x 10-" M. The saporin-bimAb mixture was also effective in blocking the phytohaemagglutinin-driven proliferation of normal lymphocytes, whereas it displayed the same level of toxicity exerted by saporin alone on an irrelevant CD25-negative cell line (EBV-infected B lymphoblastoid cell line). From these results it is possible to envisage a clinical use of this bimAb as a cytotoxic agent for CD25 + leukaemias and lymphomas, as well as an immunosuppressive agent for severe immune disorders such as graft-vs-host disease (GVHD) and transplanted organ rejection.
The use of monoclonal antibodies to kill selected cell populations has come under intense investigation in recent years. One of the possible approaches is the chemical linkage of a toxic moiety to a monoclonal antibody to produce 'immunotoxins' recognising a molecule restricted to the unwanted cell population (reviewed in Frankel, 1988) . Ricin A chain is the most common toxic moiety used so far, but several singlechain ribosome-inactivating proteins (type 1 RIPs) are also available, which are easier and safer to purify, and can be used to prepare potent immunotoxins ).
An alternative approach to conventional immunotoxins, to selectively deliver toxic moieties to neoplastic cell populations, is the use of bispecific monoclonal antibodies (bimAbs) (Glennie et al., 1988; Laky et al., 1987) , which simultaneously recognise a toxin and a tumour-associated antigen.
Lymphocyte activation antigens represent appropriate targets for antibody-driven drug delivery in haematopoietic malignancies (Engert et al., 1990; Tazzari et al., 1992a,b) . In fact some of them are not expressed on vital tissues (Herve' et al., 1990; Falini et al., 1992) , such as liver, kidney, central nervous system, heart, vessels and lung. Thus it has been possible to devise in vitro and in vivo models of drug targeting by utilising monoclonal antibodies recognising the CD25 and the CD30 lymphoid activation antigens (Engert et al., 1990; Tazzari et al., 1992a,b) , expressed on well-defined neoplastic lymphoid populations, such as Hodgkin's lymphomas, anaplastic large cell lymphomas (ALCL), and adult T-cell leukaemia (ATL).
To date bimAbs (Milstein & Cuello, 1984) have been mainly generated in order to target cytotoxic effectors to tumours (Staerz & Bevan, 1986; Lanzavecchia & Scheidegger, 1987; Ferrini et al., 1989; Ferrini et al., 1991) . A small series of bimAb have also been obtained to target RIPs to haematological neoplasias (Glennie et al., 1988) . Good preclinical in vitro and in vivo results were described, and clinical trials are also ongoing (Bonardi et al., 1992) . In this study we described a bimAb, secreted by a hybrid hybridoma, which is capable of recognising the CD25 molecule and saporin. This bimAb is able to specifically enhance the toxicity of free saporin against CD25 + targets. In fact, in the presence of saporin, the bimAb is able to induce killing of Hodgkin's-derived and ATL-derived CD25 + cell lines, as well as to inhibit phytohaemagglutinin (PHA)-driven proliferation of normal lymphocytes; on the contrary the same bimAb is ineffective on a lymphoblastoid cell line (LCL) lacking CD25 surface expression.
Materials and methods
Ribosome-inactivating proteins Saporin, PAP-S, PAP-L, momordin and gelonin were prepared as described by Barbieri et al. (1987) L-glutamine (Flow) .
The MAR93 (IgGI) hybridoma produces an anti-CD25 mAb (Lopez Botet et al., 1986) . Hypoxanthine-guanine phosphoribosyltransferase (HGPRT)-deficient mutants of the CY12.14 hybridoma were selected by culture in the presence of increasing amounts of 8-azaguanine (1 to 50 jg ml-') (Sigma, St. Louis, MO). Hybrid mutants were cloned by limiting dilution and tested for HAT sensitivity and antibody production.
Cellfusion and screening of hybrid hybridomas The HGPRT-CY12.14 clone was fused with an iodoacetamide-inactivated MAR93 hybridoma cells at a 1: 1 ratio using a standard polyethylene glycol fusion protocol (Clark & Waldman, 1987; Suresh et al., 1986) BimAb purification Anti-saporin/anti-CD25 bimAb was purified from ascitic fluid by affinity chromatography on saporin coupled with Sepharose (Pharmacia). CnBr-activated sepharose (4 ml) was coupled with purified saporin (10 mg) previously dialysed against coupling buffer (NaHCO3 0.1 M pH 8.3, NaCl 0.5 M). Ascites was dialysed against 1O mM Tris (pH 7.5) and then incubated with saporin-sepharose for 1 h at 4°C. The elution of the bound material was performed by applying 100 mM glycine pH 4 and 100 mM glycine pH 2.5. The eluted fractions were collected in tubes containing an appropriate volume of 1 M Tris pH 8.0 to neutralise the pH. Reactivity of the purified bimAb with CD25 + targets was further checked by immunofluorescence, as described below.
Cell lines
Two different CD25 + cell lines have been used throughout the study: L540 (a kind gift of Dr A. Engert concentrations of bimAb (from 10-' to 10-13 M) were tested, in the presence of saporin (from 10-8 to 10-13 M) in order to titrate both reagents. Appropriate control samples were run with cells alone, saporin alone, parental mAbs alone, or saporin plus parental mAbs, mixed together. After 24 h of incubation 2 iCi of 3H-Leucine (Amersham) were added to each well. After additional 18 h the cells were harvested onto glass fiber filters by a cell harvester (ICN-Flow), and the radioactivity was evaluated by a P-computer (Packard), as already described (Tazzari et al., 1992a,b P3U1 myeloma. All hybrids secreted IgGI mAbs which reacted with saporin in an ELISA assay, while they failed to react with other RIPs -momordin, gelonin, ricin-A chain, PAP-S and PAP-L. These results were confirmed by western blot analysis which showed that mAbs only reacted with the 30 kD saporin molecule (data not shown). We next investigated whether the three mAbs could interfere with the ribosome-inactivating activity of saporin in a cell-free protein synthesis inhibition assay (Stirpe et al., 1983; Bolognesi et al., 1992) . Two of them (CY56 and CY62) displayed >80% of inhibition of the ribosome-inactivating activity, while the third (CY12.14) had virtually no inhibitory activity. To exclude the possibility of inhibitory effects on the ribosome-inactivating activity of saporin, the CY12.14 hybridoma was used for bimAb production.
Selection of a hybrid hybridoma producing anti-saporinl anti-CD25 bimAbs To produce hybrid hybridomas secreting bimAbs a HGPRTdeficient CY12.14 anti-saporin hybridoma clone was fused with chemically inactivated cells of the anti-CD25 MAR93 hybridoma. After selection in HAT medium, hybrid hybridoma supernatants were screened for their ability to react simultaneously with saporin in ELISA and with CD25 + cells in immunofluorescence assays. Hybrids were repeatedly subcloned by limiting dilution and several subclones with double reactivity were selected. The supernatant of selected clones was then analysed for its ability to enhance saporin toxicity against CD25 + L540 target cells in a 3H-leucine uptake assay. The TC37 subclone displayed the highest activity in this assay, while the supernatant of other hybrid hybridoma subclones had less or no effect (data not shown). This finding may be related to either chromosomal instability, leading to the loss of Ig genes, or to the secretion of different amounts of correctly assembled bispecific antibody compared to other possible combinations of secreted antibodies (Milstein & Cuello, 1984) . BimAb was then purified from TC37 hybrid hybridoma ascites by affinity chromatography on a saporin-Sepharose column and utilised for further studies.
BimAb reactivity The CD25 + L540 and MT2 cell lines strongly reacted with the bimAb or with the parental anti-CD25 mAb as assayed by immunofluorescence, whereas they did not react with the anti-saporin CY12.14 mAb (Figure 1) . In addition the bimAb reacted with 20-30% of 48 h PHA-stimulated normal lymphocytes, but not with a CD25-negative (EBV)-transformed B LCL (data not shown). Thus the bimAb recognising both CD25 antigen and saporin maintains the capability of selectively recognising CD25 + cells.
Effect of bimAb-saporin combinations on protein synthesis inhibition Titration experiments using serial concentrations of both bimAb and saporin were performed with the L540 and MT2 CD25 + cell lines. As shown in Figure 2b protein synthesis by L540 cell line was inhibited by saporin with an ICs (concentrations giving 50% inhibition in comparison to control values) of 8 x 10-12 M, in the presence of I0-9M of bimAb, which was the optimal concentration for enhancing saporin toxicity. (Figure 3a) . A CD25-negative EBV-transformed LCL was used as an irrelevant target in a 3H-leucine uptake assay. No enhancement of saporin specific toxicity was obtained by testing all the combinations of bimAb and saporin, as described above (data not shown).
Cytotoxic effects of bimAb-saporin combination To verify that cells were indeed killed by bimAb-saporin combination, we evaluated cell viability after 48 h of incubation. Trypan blue-dye exclusion assay demonstrated that L540 cells were efficiently killed (only 2-1 1% of viable cells) at concentrations of bimAb ranging from 10-8 M to 10-9 M in the presence of saporin concentrations in the same range. Under the same conditions saporin alone induced only a partial loss of viability at a concentration of 10-8 M (67% of viable cells) ( Table I) .
Inhibition of 3H-thymidine incorporation on PHA-stimulated lymphocytes Since the CD25 antigen is expressed on normal Tlymphocytes upon activation, we investigated whether combinations of bimAb and saporin were effective in blocking lo 14 lo-13 10-12 10-11 1-C 10-9 10-on Concentration ( Altogether, these results indicate that the anti-CD25/antisaporin bimAb is able to efficiently target the toxic activity of saporin against both normal and neoplastic CD25 + lymphoid cells.
Discussion
In this study we described a bimAb recognising both the CD25 antigen and saporin, one of the most powerful RIPs type 1 (Stirpe et al., 1983; Thorpe et al., 1985; Stirpe et al., 1992; Bolognesi et al., 1992 usually a lower degree of sensitivity (Tazzari et al., 1992a,b) . The ability of the bimAb to enhance saporin toxicity was strictly dependent on its double specificity, since parental (anti-saporin or anti-CD25) mAbs, either alone or in combination, were uneffective. It should be pointed out that the double specificity of the bimAb was demonstrated by its ability to recognise CD25 + target cells after the affinity chromatography purification on saporin-Sepharose. This purification procedure allowed the removal of antibody species not reacting with saporin (such as parental anti-CD25 mAb) secreted by the hybrid hybridoma, while parental anti-saporin mAb co-eluted together with bimAb. Therefore, the complete removal of other antibody species (such as parental anti-saporin mAb) from bimAb preparations, by the use of additional purification steps, may result in an enhancement of bimAb targeting activity.
One of the basic conditions for a possible in vivo targeting is the reactivity of the reagent of choice with a restricted cell population, excluding vital tissues. The CD25 antigen could be an optimal choice, since in normal healthy individuals it is expressed only on small fractions of activated B-and Tlymphocytes (Herve' et al., 1990) . The CD25 molecule represents the a-chain of the interleukin-2 (IL-2) receptor complex. This chain, together with the IL-2 receptor P chain, forms the high affinity IL2-receptor which is expressed on both T-and B-lymphocytes after activation (Dukovich et al., 1987; Robb et al., 1987) . Thus CD25 plays a key role in the control of IL-2-driven T and B lymphocyte proliferation and in the clonal expansion of antigen-specific lymphocytes. Therefore the possible clinical applications of anti-CD25 mAbs may be the targeting of CD25 + lymphoid cell tumours, or of CD25 + normal cells in severe immune disorders such as GVHD and transplanted organ rejection.
In a previous study we described an immunotoxin obtained by conventional chemical linking of a CD25 mAb and saporin, with a very high specific in vitro activity (IC50 of approximately 10-12 M as linked saporin), which was designed for the therapy of steroid-resistant GVHD, as well as of CD25 + lymphomas (Tazzari et al., 1992b) . Moreover our group recently reported in vitro and in vivo results obtained in CD30 + lymphoid neoplasias with an immunotoxin containing an anti-CD30 mAb (Ber-H2) chemically linked to saporin (Tazzari et al., 1992a; Falini et al., 1992) . Encouraging clinical results confirmed the high activity of saporin-containing conjugates demonstrated in the in vitro assays (Thorpe et al., 1985; Siena et al., 1988; Tazzari et al., 1988) . The major limitations were represented by (i) the higher toxicity of linked saporin in comparison to free saporin (LD50 in mice 1 mg kg-' vs 1O mg kg' (Thorpe et al., 1985; Marcucci et al., 1989) ) and (ii) the formation of anti-saporin and anti-mouse IgG antibodies, with increased risk of anaphylaxis due to a possible enhanced immunogenicity of linked saporin (Falini et al., 1992 ; F. Stirpe, personal observations). Thus the possible advantages of the in vivo use of bispecific antibodies recognising both the relevant target and saporin are (i) the possibility of in vivo targeting with higher doses of mAb and saporin; (ii) a lower probability of anaphylaxis after repeated administrations and (iii) to avoid the partial and in some cases (gelonin) almost total inactivation of RIPs which may occur during the chemical conjugation to antibodies (Bolognesi et al., 1992) .
Immunotoxins consisting of mAbs and toxic moieties may provide efficient tools to reduce the toxicities of conventional chemotherapeutic and immunosuppressive protocols. The bimAb herein described could provide the basis for a clinical trial, devised to effectively target and kill CD25 + unwanted populations, both normal and of neoplastic origin. In this context bispecific antibodies recognising saporin and B-cell antigens have recently been reported and were used in a clinical trial in patients with CD22 + low grade lymphomas, with encouraging clinical results (Bonardi et al., 1992) .
